First Two Cases Of XDR-TB Confirmed In Botswana, Ministry Of Health Say

Main Category: Tuberculosis
Also Included In: MRSA / Drug Resistance;  HIV / AIDS;  Respiratory / Asthma
Article Date: 18 Jan 2008 - 11:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:5 stars

5 (1 votes)

Healthcare Prof:not yet rated


Botswana's Ministry of Health on Wednesday said it has confirmed the country's first two cases of extensively drug-resistant tuberculosis, which is resistant to the two most potent first-line treatments and some of the available second-line drugs, the AP/Google.com reports. The health ministry also said it has confirmed 100 cases of multi-drug resistant TB. XDR-TB can be "particularly lethal" in Southern Africa because it often affects people living with HIV/AIDS, the AP/Google.com reports (Motseta, AP/Google.com, 1/16).

According to a report released in November 2007 by the Forum for Collaborative HIV Research, about one-third of the approximately 40 million HIV-positive people worldwide also are living with TB. Deaths from HIV/TB coinfection are five times higher than deaths from TB alone, the report said. It found that about half of all new TB cases in sub-Saharan Africa occur among HIV-positive people and that HIV/TB coinfection could be fueling the increase in drug-resistant strains of TB. About 10% of people living with HIV/AIDS develop TB annually, according to the report. Approximately 90% of people living with HIV/AIDS will die within months of contracting TB, Stephen Lawn, a researcher at the University of Cape Town, said (Kaiser Daily HIV/AIDS Report, 11/2/07).

XDR-TB has been reported in other parts of the world, and a number of cases have been diagnosed in the former Soviet republics. In Southern Africa, more than 400 cases of the disease have been reported in South Africa, and a handful of cases have been diagnosed in Mozambique. Although health officials have said the disease likely has spread to neighboring countries like Swaziland and Lesotho, XDR-TB has not been diagnosed in other Southern African nations because of a lack of laboratory facilities. In addition to South Africa, Botswana is the only other country in Southern Africa with adequate laboratory capacity to diagnose XDR-TB, according to the AP/Google.com.

Batatu Tafa, permanent secretary of Botswana's health ministry, said health care workers who provide TB treatment should receive examinations if they develop any symptoms. Tafa also called on HIV-positive people in the country to receive TB screenings (AP/Google.com, 1/16).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Article adapted by Medical News Today from original press release.
Visit our tuberculosis section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Kaiser. "First Two Cases Of XDR-TB Confirmed In Botswana, Ministry Of Health Say." Medical News Today. MediLexicon, Intl., 18 Jan. 2008. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/94336.php>

APA
Kaiser. (2008, January 18). "First Two Cases Of XDR-TB Confirmed In Botswana, Ministry Of Health Say." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/94336.php.

Please note: If no author information is provided, the source is cited instead.


Tuberculosis

Most Popular Articles



Follow Our Tuberculosis News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Tuberculosis Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »